MCID: ERY017
MIFTS: 54

Erythema Elevatum Diutinum

Categories: Rare diseases, Skin diseases, Cardiovascular diseases, Bone diseases

Aliases & Classifications for Erythema Elevatum Diutinum

MalaCards integrated aliases for Erythema Elevatum Diutinum:

Name: Erythema Elevatum Diutinum 12 49 55 41 14 69

Characteristics:

Orphanet epidemiological data:

55
erythema elevatum diutinum
Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060567
ICD10 32 L95.1
MeSH 41 C535509
Orphanet 55 ORPHA90000
MESH via Orphanet 42 C535509
UMLS via Orphanet 70 C0263398
ICD10 via Orphanet 33 L95.1
UMLS 69 C0263398

Summaries for Erythema Elevatum Diutinum

NIH Rare Diseases : 49 Erythema elevatum diutinum is a rare type of chronic cutaneous vasculitis characterized by red, purple, brown or yellow papules, plaques (thick, red patches of skin), or nodules.These lesions are located mainly on the knees, elbows, hands, feet, face, genitals and buttocks. Although it is a chronic condition, most cases respond well to treatment with dapsone. The cause of this condition remains unknown.  Last updated: 4/13/2010

MalaCards based summary : Erythema Elevatum Diutinum is related to dermatitis herpetiformis and vasculitis, and has symptoms including skin rash, arthralgia and myalgia. An important gene associated with Erythema Elevatum Diutinum is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and Cell adhesion molecules (CAMs). The drugs Heparin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include skin, b cells and bone, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A vasculitis characterised by red, purple, brown or yellow papules (raised spot), plaques, or nodules, found on the backs of the hands, other extensor surfaces overlying joints, and on the buttocks.

Wikipedia : 72 Erythema elevatum diutinum is a form of... more...

Related Diseases for Erythema Elevatum Diutinum

Diseases related to Erythema Elevatum Diutinum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 dermatitis herpetiformis 30.5 CD40LG CD79A
2 vasculitis 30.4 CD40LG CD79A S100A9
3 acquired immunodeficiency syndrome 30.0 CD34 CD40LG CD79A
4 systemic lupus erythematosus 28.7 CD40LG CD79A GATA3 S100A9
5 trichomoniasis 10.4 CD79A CXCL8
6 arthritis 10.4
7 clonorchiasis 10.4 CD79A CXCL8
8 vaginal disease 10.4 CD79A CXCL8
9 rheumatoid arthritis 10.4
10 selective igg deficiency disease 10.4 CD40LG CD79A
11 c1q nephropathy 10.4 CD40LG CD79A
12 meningovascular neurosyphilis 10.4 CD40LG CD79A
13 alpha chain disease 10.4 CD40LG CD79A
14 brill-zinsser disease 10.4 CD40LG CD79A
15 cork-handlers' disease 10.4 CD40LG CD79A
16 salpingo-oophoritis 10.4 CD40LG CD79A
17 early yaws 10.4 CD40LG CD79A
18 ventilation pneumonitis 10.4 CD40LG CD79A
19 chronic interstitial cystitis 10.4 CD40LG CD79A
20 axillary adenitis 10.3 CD40LG CD79A
21 cryofibrinogenemia 10.3 CD40LG CD79A
22 trichostrongyloidiasis 10.3 CD40LG CD79A
23 subacute bacterial endocarditis 10.3 CD40LG CD79A
24 heterophyiasis 10.3 CD40LG CD79A
25 immunoglobulin g deficiency 10.3 CD40LG CD79A
26 transient hypogammaglobulinemia of infancy 10.3 CD40LG CD79A
27 hyperglobulinemic purpura 10.3 CD40LG CD79A
28 gastroduodenitis 10.3 CD40LG CD79A
29 bacterial conjunctivitis 10.3 CD40LG CD79A
30 heavy chain disease 10.3 CD40LG CD79A
31 ophthalmia neonatorum 10.3 CD40LG CD79A
32 immunoglobulin a deficiency 1 10.3 CD40LG CD79A
33 parotid disease 10.3 CD40LG CD79A
34 cerebral arteritis 10.3 CD40LG CD79A
35 selective immunoglobulin deficiency disease 10.3 CD40LG CD79A
36 geniculate herpes zoster 10.3 CD40LG CD79A
37 sporotrichosis 10.3 CD40LG CD79A
38 fallopian tube disease 10.3 CD40LG CD79A
39 hyperimmunoglobulin syndrome 10.3 CD40LG CD79A
40 congenital syphilis 10.3 CD40LG CD79A
41 keratitis, hereditary 10.3
42 polyclonal hypergammaglobulinemia 10.3 CD40LG CD79A
43 monoclonal paraproteinemia 10.3 CD40LG CD79A
44 salpingitis 10.3 CD40LG CD79A
45 ocular toxoplasmosis 10.3 CD40LG CD79A
46 parasitic ichthyosporea infectious disease 10.3 CD40LG CD79A
47 dysgammaglobulinemia 10.3 CD40LG CD79A
48 congenital hypogammaglobulinemia 10.3 CD40LG CD79A
49 acute maxillary sinusitis 10.3 CD40LG CD79A
50 rhinosporidiosis 10.3 CD40LG CD79A

Graphical network of the top 20 diseases related to Erythema Elevatum Diutinum:



Diseases related to Erythema Elevatum Diutinum

Symptoms & Phenotypes for Erythema Elevatum Diutinum

Human phenotypes related to Erythema Elevatum Diutinum:

55 31 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 skin rash 55 31 hallmark (90%) Very frequent (99-80%) HP:0000988
2 arthralgia 55 31 hallmark (90%) Very frequent (99-80%) HP:0002829
3 myalgia 55 31 occasional (7.5%) Occasional (29-5%) HP:0003326
4 abnormal blistering of the skin 55 31 frequent (33%) Frequent (79-30%) HP:0008066
5 increased antibody level in blood 55 31 frequent (33%) Frequent (79-30%) HP:0010702
6 vasculitis in the skin 55 31 hallmark (90%) Very frequent (99-80%) HP:0200029
7 skin nodule 55 31 occasional (7.5%) Occasional (29-5%) HP:0200036
8 skin vesicle 55 31 frequent (33%) Frequent (79-30%) HP:0200037

MGI Mouse Phenotypes related to Erythema Elevatum Diutinum:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.8 CD40LG CD79A GATA3 PECAM1 S100A9 TBX21
2 hematopoietic system MP:0005397 9.76 CD79A F13A1 GATA3 PECAM1 S100A9 TBX21
3 homeostasis/metabolism MP:0005376 9.56 CD79A F13A1 GATA3 PECAM1 S100A9 TBX21
4 immune system MP:0005387 9.17 CD40LG CD79A GATA3 PECAM1 S100A9 TBX21

Drugs & Therapeutics for Erythema Elevatum Diutinum

Drugs for Erythema Elevatum Diutinum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
2
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
3
Budesonide Approved Phase 4 51333-22-3 5281004 63006
4
Canagliflozin Approved Phase 4 842133-18-0
5
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418
6
Insulin Glargine Approved Phase 4 160337-95-1
7
Insulin-glulisine Approved Phase 4 207748-29-6
8
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 4091 14219
9
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6 32051 23994
10
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
11
Nateglinide Approved, Investigational Phase 4 105816-04-4 60026
12
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
13
Goserelin Approved Phase 4 65807-02-5 5311128 47725
14
Leuprolide Approved, Investigational Phase 4 53714-56-0 657181 3911
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 143 6006
17 Hormone Antagonists Phase 4,Phase 3,Phase 2
18 Hormones Phase 4,Phase 3,Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
20 calcium heparin Phase 4,Phase 3
21 Antimetabolites Phase 4,Phase 3,Phase 2
22 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2
24 Dermatologic Agents Phase 4,Phase 3,Phase 2
25 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
27 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
28 Vitamin B Complex Phase 4,Phase 3,Phase 2
29 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
30 Contraceptive Agents Phase 4,Phase 3,Phase 2
31 Adrenergic Agents Phase 4,Phase 3
32 Adrenergic Agonists Phase 4,Phase 3
33 Adrenergic beta-2 Receptor Agonists Phase 4
34 Adrenergic beta-Agonists Phase 4
35 Anti-Asthmatic Agents Phase 4,Phase 3
36 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
37 Autonomic Agents Phase 4,Phase 3,Phase 2
38 Bronchodilator Agents Phase 4,Phase 3
39 Budesonide, Formoterol Fumarate Drug Combination Phase 4
40 Formoterol Fumarate Phase 4
41 glucocorticoids Phase 4,Phase 3,Phase 2
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
43 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
44 Respiratory System Agents Phase 4,Phase 3
45 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
46 Biphasic Insulins Phase 4,Phase 3
47 Coagulants Phase 4
48 insulin Phase 4,Phase 3
49 Insulin aspart, insulin aspart protamine drug combination 30:70 Phase 4,Phase 3
50 Insulin degludec, insulin aspart drug combination Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 86)

# Name Status NCT ID Phase Drugs
1 Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma Completed NCT02062463 Phase 4 Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX;SYMBICORT TURBOHALER budesonide and formoterol fumarate
2 A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus Completed NCT01989754 Phase 4 Placebo;Canagliflozin, 100 mg;Canagliflozin, 300 mg
3 Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients Completed NCT00965549 Phase 4 INSULIN GLARGINE (HOE901);Insulin aspart;Insulin Glulisine
4 Local Phase 4 Pan-European SMART Study Completed NCT00463866 Phase 4 Budesonide/formoterol
5 AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers Completed NCT01084577 Phase 4
6 A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study) Recruiting NCT02616666 Phase 4 Dapagliflozin;Standard of Care
7 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. Active, not recruiting NCT02752776 Phase 4 Secukinumab
8 A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage Terminated NCT01661140 Phase 4 Methotrexate (stable dose);Tocilizumab;Methotrexate (tapering dose)
9 GP Extended Action Triptorelin Terminated NCT01673984 Phase 4 Decapeptyl® SR 22.5mg;Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
10 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Unknown status NCT00559858 Phase 3
11 Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00392535 Phase 3 cyproterone acetate;releasing hormone agonist therapy
12 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
13 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
14 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed NCT00412984 Phase 3 warfarin;apixaban
15 A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease Completed NCT00501059 Phase 3 Aspirin (Acetylsalicylic acid, BAYE4465);Placebo
16 A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer Completed NCT01262651 Phase 3 Sativex®;Placebo (GA-0034)
17 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
18 A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Completed NCT00196794 Phase 3 Tolevamer potassium-sodium (GT267-004)
19 A Study of RoActemra/Actemra (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Completed NCT02046603 Phase 3 DMARDs;corticosteroids;tocilizumab [RoActemra/Actemra]
20 Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension Completed NCT01788358 Phase 3 Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106);Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
21 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed NCT01764633 Phase 3 Placebo
22 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer Completed NCT01424566 Phase 3 Sativex®;Placebo (product code GA0034)
23 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed NCT01336023 Phase 3 insulin degludec/liraglutide;insulin degludec;liraglutide
24 Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT01313676 Phase 3 fluticasone furoate/vilanterol;fluticasone furoate;vilanterol
25 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy Completed NCT00883753 Phase 3 tocilizumab [RoActemra/Actemra]
26 An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. Completed NCT00750880 Phase 3 tocilizumab [RoActemra/Actemra]
27 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3 linagliptine 5 mg;linagliptine 5 mg and pioglitazone 30 mg
28 A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain Completed NCT01439100 Phase 3 Oxycodone/Naloxone Prolonged Release tablets;Placebo
29 Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients Completed NCT00660907 Phase 3 dapagliflozin;glipizide;metformin hydrochloride
30 BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes Completed NCT00602472 Phase 3 linagliptin;placebo
31 Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00400153 Phase 3 Atrovent Respimat (20 mcg);COMBIVENT MDI (36/206 mcg);Combivent Respimat (20 mcg/100 mcg);Placebo via corresponding inhaler for blinding purposes
32 Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes Completed NCT00184600 Phase 3 biphasic insulin aspart;insulin detemir;insulin aspart
33 Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) Completed NCT00479661 Phase 3 Dexmedetomidine;Propofol
34 Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain Completed NCT01337089 Phase 3 Sativex®
35 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3 Intravenous;Bortezomib
36 A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer Completed NCT00069121 Phase 3 capecitabine [Xeloda];Oxaliplatin;Oxaliplatin;Leucovorin;5 FU
37 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed NCT00633893 Phase 3 Apixaban;Placebo
38 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
39 Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours Recruiting NCT02804815 Phase 3 Aspirin 100mg;Aspirin 300mg;Placebo 100mg;Placebo 300mg
40 Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease Recruiting NCT02914600 Phase 3 Filgotinib;Placebo
41 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Recruiting NCT02914561 Phase 3 Filgotinib;Placebo to match filgotinib
42 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Recruiting NCT02914535 Phase 3 Filgotinib;Placebo
43 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Recruiting NCT02914522 Phase 3 Filgotinib;Placebo to match filgotinib
44 A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Recruiting NCT02615873 Phase 3 Accordion Pill™ Carbidopa/Levodopa
45 A Study to Assess the Efficacy and Safety of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients Recruiting NCT02605434 Phase 3 Accordion Pill™ Carbidopa/Levodopa;Sinemet®;Placebo -AP-CD/LD;Placebo- Sinemet
46 An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease Recruiting NCT02542696 Phase 3 APL-130277
47 Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Recruiting NCT02540954 Phase 3 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
48 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) Recruiting NCT03160885 Phase 3 Tralokinumab;Placebo
49 STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial Recruiting NCT00268476 Phase 2, Phase 3 Celecoxib;Docetaxel;Prednisolone;ADT;Zoledronic Acid;Abiraterone;Enzalutamide;Metformin;Transdermal Oestradiol
50 Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery Active, not recruiting NCT00301925 Phase 3 capecitabine;cyclophosphamide;epirubicin hydrochloride;fluorouracil;methotrexate

Search NIH Clinical Center for Erythema Elevatum Diutinum

Cochrane evidence based reviews: erythema elevatum diutinum

Genetic Tests for Erythema Elevatum Diutinum

Anatomical Context for Erythema Elevatum Diutinum

MalaCards organs/tissues related to Erythema Elevatum Diutinum:

38
Skin, B Cells, Bone, Neutrophil, Prostate, Liver, Myeloid

Publications for Erythema Elevatum Diutinum

Articles related to Erythema Elevatum Diutinum:

(show top 50) (show all 194)
# Title Authors Year
1
Erythema elevatum diutinum with pustule formation: An unusual finding. ( 29292528 )
2018
2
Late-stage nodular erythema elevatum diutinum mimicking sclerotic fibroma. ( 29068068 )
2018
3
Erythema elevatum diutinum-like vasculitis secondary to cocaine adulterated with levamisole. ( 29423942 )
2018
4
Erythema, Elevatum Diutinum ( 28846276 )
2017
5
A rare case of erythema elevatum diutinum presenting as diffuse neuropathy. ( 28050587 )
2017
6
Erythema elevatum diutinum presenting with palmoplantar keratoderma. ( 28512994 )
2017
7
Erythema elevatum diutinum involving palms and soles: a case report and literature review. ( 28469800 )
2017
8
Erythema Elevatum Diutinum. ( 28183422 )
2017
9
Erythema elevatum diutinum in a healthy child. ( 28397292 )
2017
10
Erythema elevatum diutinum in Crohn's disease-associated Spondyloarthritis - a rare vasculitis, an unusual association. ( 28917218 )
2017
11
Vesiculobullous variant of erythema elevatum diutinum. ( 28639709 )
2017
12
Erythema elevatum diutinum-associated with loss of the uvula. ( 28443312 )
2017
13
Late-Stage Erythema Elevatum Diutinum Mimicking a Fibroblastic Tumor: A Potential Pitfall. ( 29293121 )
2017
14
Granuloma Faciale and Erythema Elevatum Diutinum in Relation to Immunoglobulin G4-Related Disease: An Appraisal of 32 Cases. ( 27124923 )
2016
15
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. ( 27097593 )
2016
16
Erythema elevatum diutinum in acquired immune deficiency syndrome: Can it be an immune reconstitution inflammatory syndrome? ( 27190420 )
2016
17
Erythema elevatum diutinum in association with IgA monoclonal gammopathy: A rare case report. ( 27559509 )
2016
18
Chronic Localized Fibrosing Leukocytoclastic Vasculitis Associated With Lymphedema, Intralymphatic and Intravascular Lymphocytosis, and Chronic Myelogenous Leukemia: A Case Report of Unilateral Erythema Elevatum Diutinum. ( 27930381 )
2016
19
Erythema elevatum diutinum and hypothyroidism: coincidence or causal relationship? ( 26375227 )
2015
20
A Case of Erythema Elevatum Diutinum With Pancytopenia: Focus on Dapsone-Induced Hematologic Side Effects and Colchicine as a Safe Treatment Option. ( 26461818 )
2015
21
Erythema elevatum diutinum coexisting with ankylosing spondylitis. ( 27708930 )
2015
22
A case of mistaken identity: unilateral erythema elevatum diutinum associated with IgA paraproteinaemia. ( 25754401 )
2015
23
Erythema elevatum diutinum: an atypical presentation. ( 25521326 )
2015
24
An unusual case of Sweet syndrome in a child: overlapping presentation with erythema elevatum diutinum. ( 24521734 )
2014
25
Erythema elevatum diutinum: a review of presentation and treatment. ( 25288365 )
2014
26
Case of Erythema Elevatum Diutinum Associated With IgA Paraproteinemia Successfully Controlled With Thalidomide and Plasma Exchange. ( 25257541 )
2014
27
An atypical distribution of erythema elevatum diutinum. ( 24479627 )
2014
28
Erythema elevatum diutinum in association with dermatitis herpetiformis. ( 24616856 )
2014
29
Erythema Elevatum Diutinum (EED): A Distinctive Vasculitis with Acute-on-Chronic Features. ( 24652434 )
2014
30
An unusual case of erythema elevatum diutinum with penile and laryngeal manifestations. ( 24413401 )
2014
31
Nodular Erythema Elevatum Diutinum Mimicking Kaposi's Sarcoma in a Human Immunodeficiency Virus Infected Patient. ( 25484391 )
2014
32
Erythema elevatum diutinum: a new vesiculobullous case. ( 24001509 )
2013
33
Erythema elevatum diutinum. ( 23442466 )
2013
34
Novel use of topical dapsone 5% gel for erythema elevatum diutinum: safer and effective. ( 23652900 )
2013
35
Atypical erythema elevatum diutinum or extrafacial granuloma faciale? ( 23253514 )
2013
36
Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease. ( 24073904 )
2013
37
Erythema elevatum diutinum. ( 23487831 )
2013
38
A case of erythema elevatum diutinum associated with peripheral ulcerative keratitis. ( 22309340 )
2012
39
Successful combination therapy with dapsone and cyclosporine for erythema elevatum diutinum with unusual appearance. ( 22132683 )
2012
40
Alternative procedure to allow continuation of dapsone therapy despite serious adverse reaction in a case of dapsone-sensitive erythema elevatum diutinum. ( 22508198 )
2012
41
Erythema elevatum diutinum with oral ulceration. ( 22284024 )
2012
42
Is IgA antineutrophil cytoplasmic antibody a marker for patients with erythema elevatum diutinum? A further three cases demonstrating this association. ( 21143463 )
2011
43
Erythema elevatum diutinum mimicking a vesiculobullous disease. ( 22126877 )
2011
44
Erythema elevatum diutinum associated with peripheral ulcerative keratitis. ( 20569285 )
2011
45
Erythema elevatum diutinum associated with dermatomyositis. ( 21496713 )
2011
46
Progressive keratolysis with pseudopterygium associated with erythema elevatum diutinum. ( 21211842 )
2011
47
Erythema elevatum diutinum: an "idiopathic" case. ( 21810392 )
2011
48
Acceleration of pulmonary interstitial fibrosis in a patient with myeloperoxidase-antineutrophil cytoplasmic antibody-positive erythema elevatum diutinum. ( 21839335 )
2011
49
Erythema elevatum diutinum associated with scleritis. ( 23130212 )
2011
50
Erythema elevatum diutinum in systemic lupus erythematosus. ( 20652813 )
2011

Variations for Erythema Elevatum Diutinum

Expression for Erythema Elevatum Diutinum

Search GEO for disease gene expression data for Erythema Elevatum Diutinum.

Pathways for Erythema Elevatum Diutinum

GO Terms for Erythema Elevatum Diutinum

Cellular components related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD34 CD40LG CD79A PECAM1

Biological processes related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.58 CD34 CD40LG TBX21
2 T cell differentiation GO:0030217 9.46 GATA3 TBX21
3 B cell proliferation GO:0042100 9.43 CD40LG CD79A
4 leukocyte cell-cell adhesion GO:0007159 9.37 CD40LG PECAM1
5 positive regulation of interleukin-10 production GO:0032733 9.32 CD34 CD40LG
6 positive regulation of interleukin-4 production GO:0032753 9.26 CD40LG GATA3
7 negative regulation of interleukin-2 production GO:0032703 9.16 GATA3 TBX21
8 lymphocyte migration GO:0072676 8.96 GATA3 TBX21
9 glomerular endothelium development GO:0072011 8.62 CD34 PECAM1

Sources for Erythema Elevatum Diutinum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....